Carl Zeiss Meditec
supporting healthcare professionals in setting new standards of care in ophthalmology/optometry; neuro, ENT, spine, dental and gynecologic surgery; and intraoperative radiotherapy
Carl Zeiss Meditec AG, listed on Germany’s TecDAX and SDAX under ISIN DE0005313704, is a leading international medical technology company dedicated to improving patient outcomes through innovative products and solutions. The company develops and supplies comprehensive technologies for the diagnosis and treatment of eye diseases, including implants, consumables, and advanced visualization systems for microsurgery. Its solutions are designed to support healthcare professionals in delivering high-quality care and improving the quality of life for patients worldwide.
Headquartered in Jena, Germany, Carl Zeiss Meditec maintains subsidiaries across Europe, North America, and Asia, with over half of its workforce located in the United States, Japan, Spain, and France. The company also operates the Center for Application and Research (CARIn) in Bangalore, India, and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthening its presence in emerging markets.
Carl Zeiss Meditec AG employs 5,784 professionals globally and reported revenue of €2,228 million for the fiscal year 2024/25 ending September 30. Approximately 39 percent of its shares are publicly traded, while 59 percent are held by Carl Zeiss AG, a major player in the optical and optoelectronic industries.
